TY  - JOUR 
AU  - Elez, Elena
AU  - Pericay, Carles
AU  - Valladares Ayerbes, Manuel
AU  - Bando, Inmaculada
AU  - Safont, Maria Jose
AU  - Gallego, Javier
AU  - Gravalos, Cristina
AU  - Arrivi, Antonio
AU  - Carrato, Alfredo
AU  - Conde, Veronica
AU  - Ortiz, Maria Jose
AU  - Lopez, Carlos
AU  - Alonso, Beatriz
AU  - Ruiz de Mena, Inmaculada
AU  - Diaz-Rubio, Eduardo
AU  - Tabernero, Josep
AU  - Aranda, Enrique
PY  - 2019
SN  - 0007-0920
UR  - http://hdl.handle.net/20.500.11940/15918
AB  - BACKGROUND: Targeted agents are standard treatment for RAS wild-type metastatic colorectal cancer in the first- and second-line settings. This phase 2 study determined the benefit of targeting the epidermal growth factor receptor (EGFR) with...
LA  - eng
KW  - Membrane Proteins
KW  - Adult
KW  - Peritoneal Neoplasms
KW  - Proto-Oncogene Proteins B-raf
KW  - Middle Aged
KW  - GTP Phosphohydrolases
KW  - Adenocarcinoma
KW  - Lymph Nodes
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Survival Rate
KW  - Drug Eruptions
KW  - Magnesium
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Diarrhea
KW  - Lung Neoplasms
KW  - Humans
KW  - Treatment Outcome
KW  - Asthenia
KW  - Water-Electrolyte Imbalance
KW  - Liver Neoplasms
KW  - Salvage Therapy
KW  - Aged
KW  - Colorectal Neoplasms
KW  - PTEN Phosphohydrolase
TI  - A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
DO  - 10.1038/s41416-019-0537-z
T2  - BRITISH JOURNAL OF CANCER
KW  - CHUAC
VL  - 121
ER  -